New combo therapy offers hope for tough bone cancer
NCT ID NCT07479732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, apatinib and liposomal irinotecan, in people with advanced osteosarcoma (bone cancer) that has spread or come back after standard treatments. The goal is to find the safest and most effective dose and see if the combo can shrink tumors or slow cancer growth. About 56 participants will be enrolled at multiple centers in China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Experimental vaccine fights sarcoma with Patient's own immune cells
- New drug hope for rare sarcomas after chemo fails
- Dietary change explored as cancer support strategy
- New drug combo aims to stall bone sarcoma in phase 2 trial
- New hope for kids with resistant cancers: targeted drug enters trial